Is the price fair?
What AZTA's price assumes
Azenta, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 1.63× revenue.
1.63
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.8%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; revenue has grown −0.03% a year over the last three.
- Price / book
- 0.63
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.63
- EV / EBIToperating margin −29%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $30M
- Market capitalisation
- $1.07B
- 3-year revenue growth
- −0.03%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #24 of 27 by Smart Score